AU2016333538B2 - GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers - Google Patents

GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers Download PDF

Info

Publication number
AU2016333538B2
AU2016333538B2 AU2016333538A AU2016333538A AU2016333538B2 AU 2016333538 B2 AU2016333538 B2 AU 2016333538B2 AU 2016333538 A AU2016333538 A AU 2016333538A AU 2016333538 A AU2016333538 A AU 2016333538A AU 2016333538 B2 AU2016333538 B2 AU 2016333538B2
Authority
AU
Australia
Prior art keywords
hgdf
cancer
human
antibody
gdf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016333538A
Other languages
English (en)
Other versions
AU2016333538A1 (en
Inventor
Reinhard DUMMER
Markus Haake
Matthias MEHLING
Jörg WISCHHUSEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Julius Maximilians Universitaet Wuerzburg
Original Assignee
Julius Maximilians Universitaet Wuerzburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1517527.6A external-priority patent/GB201517527D0/en
Priority claimed from GBGB1607800.8A external-priority patent/GB201607800D0/en
Application filed by Julius Maximilians Universitaet Wuerzburg filed Critical Julius Maximilians Universitaet Wuerzburg
Publication of AU2016333538A1 publication Critical patent/AU2016333538A1/en
Application granted granted Critical
Publication of AU2016333538B2 publication Critical patent/AU2016333538B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016333538A 2015-10-02 2016-09-30 GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers Active AU2016333538B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1517527.6 2015-10-02
GBGB1517527.6A GB201517527D0 (en) 2015-10-02 2015-10-02 GDF-15 as a diagnosis marker to predict the clinical outcome of a treatment with immune checkpoint blockers
GB1607800.8 2016-04-29
GBGB1607800.8A GB201607800D0 (en) 2016-04-29 2016-04-29 GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
PCT/EP2016/073519 WO2017055612A1 (en) 2015-10-02 2016-09-30 Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers

Publications (2)

Publication Number Publication Date
AU2016333538A1 AU2016333538A1 (en) 2018-04-26
AU2016333538B2 true AU2016333538B2 (en) 2022-03-31

Family

ID=57123979

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016333538A Active AU2016333538B2 (en) 2015-10-02 2016-09-30 GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers

Country Status (10)

Country Link
US (2) US11262360B2 (enExample)
EP (2) EP4321866A3 (enExample)
JP (1) JP6858181B2 (enExample)
KR (1) KR102621034B1 (enExample)
AU (1) AU2016333538B2 (enExample)
CA (1) CA3000290C (enExample)
DK (1) DK3356827T3 (enExample)
ES (1) ES2968226T3 (enExample)
FI (1) FI3356827T3 (enExample)
WO (1) WO2017055612A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104853775B (zh) * 2012-09-26 2023-10-20 尤利乌斯·马克西米利安维尔茨堡大学 针对生长和分化因子15(gdf-15)的单克隆抗体
US10509045B2 (en) 2015-05-29 2019-12-17 University Of Florida Research Foundation, Incorporated Methods for diagnosing Huntington's disease
CA3000290C (en) 2015-10-02 2023-02-21 Julius-Maximilians-Universitat Wurzburg Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
EP3440100A4 (en) 2016-04-04 2020-01-22 University of Florida Research Foundation, Incorporated HANDLING EIF3 TO MODULATE A NON-ATG TRANSLATION ASSOCIATED WITH A REPETITION (RAN)
MA45113A (fr) 2016-05-24 2019-04-10 Novo Nordisk As Composés mic-1 et leur utilisation
AU2018255293B2 (en) 2017-04-17 2024-03-07 University Of Florida Research Foundation, Incorporated Regulation of RAN translation by PKR and eIF2a-P pathways
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
US12504380B2 (en) 2017-09-25 2025-12-23 University Of Florida Research Foundation, Incorporated Immunoassays for detection of ran proteins
US11216742B2 (en) 2019-03-04 2022-01-04 Iocurrents, Inc. Data compression and communication using machine learning
KR102164432B1 (ko) 2019-09-18 2020-10-13 한국과학기술원 Dna 메틸화 변이를 이용한 면역항암치료 반응성 예측방법
AU2020348916B2 (en) 2019-09-20 2025-12-18 University Of Florida Research Foundation, Incorporated Detection of antibodies against RAN proteins from serum and tissue lysates
KR102238912B1 (ko) 2020-05-27 2021-04-12 한국과학기술원 Dna 메틸화 변이 및 종양 변이 부담을 이용한 면역항암치료 반응성 예측방법
CN112162097B (zh) * 2020-07-24 2022-04-01 广州医科大学 Gdf1作为评估pd-1单抗治疗效果的生物标志物
IL302646A (en) 2020-11-10 2023-07-01 Catalym Gmbh Anti-GDF15 antibody and dosage regimen for cancer treatment
CN112698042A (zh) * 2020-12-17 2021-04-23 北京赛诺浦生物技术有限公司 检测人生长分化因子-15的荧光免疫层析试纸条及其制备方法和应用
CN113252905A (zh) * 2021-05-12 2021-08-13 北京赛诺浦生物技术有限公司 人生长分化因子-15磁微粒化学发光检测试剂盒及其应用
CN113702647B (zh) * 2021-08-31 2024-03-15 普十生物科技(北京)有限公司 人生长分化因子15即时检测试剂盒、其制备方法及其应用
KR20230046264A (ko) 2021-09-29 2023-04-05 (주)펜타메딕스 Line-1의 dna 메틸화 변이를 이용한 면역항암치료 반응성 예측방법
CN115831306A (zh) * 2023-02-23 2023-03-21 北京康博众联电子科技有限公司 一种数据分析装置、方法及计算机存储介质
CN116462757A (zh) * 2023-03-24 2023-07-21 科兴生物制药股份有限公司 Gdf15的单域抗体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015144855A1 (en) * 2014-03-26 2015-10-01 Julius-Maximilians-Universität Würzburg Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6455677B1 (en) 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
US6465181B2 (en) 1999-03-25 2002-10-15 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
WO2000070051A1 (en) 1999-05-17 2000-11-23 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrieb Von Pharmaka Mbh NEUROPROTECTIVE PROPERTIES OF GDF-15, A NOVEL MEMBER OF THE TGF-β SUPERFAMILY
US7141661B2 (en) 2000-09-08 2006-11-28 The United States Of America As Represented By The Department Of Health And Human Services Non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
DK2311873T3 (en) 2004-01-07 2018-11-26 Novartis Vaccines & Diagnostics Inc M-CSF-SPECIFIC MONOCLONAL ANTIBODY AND APPLICATIONS THEREOF
PT2441466E (pt) 2004-04-13 2014-09-09 St Vincents Hosp Sydney Agente de inibição de mic-1
WO2007067500A2 (en) 2005-12-05 2007-06-14 Genomic Health, Inc. Predictors of patient response to treatment with egfr inhibitors
CA2694863A1 (en) * 2007-08-16 2009-02-19 Garvan Institute Of Medical Research Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
US20100266707A1 (en) 2007-10-09 2010-10-21 Samuel Norbert Breit Method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1
WO2009150256A1 (en) * 2008-06-13 2009-12-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Markers for predicting response and survival in anti-egfr treated patients
KR101318549B1 (ko) 2008-09-29 2013-10-16 로슈 글리카트 아게 인간 ｉｌ17 에 대한 항체 및 이의 용도
EP2209003A1 (en) * 2009-01-16 2010-07-21 F. Hoffmann-Roche AG Means and methods for differentiating between fibrosis and cirrhosis
US7736861B1 (en) 2009-10-19 2010-06-15 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
US20120309697A1 (en) 2009-10-28 2012-12-06 Samuel Norbert Breit Methods of diagnosing and prognosing colonic polyps
US9212221B2 (en) 2010-03-03 2015-12-15 Detroit R & D, Inc. Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
JP6013915B2 (ja) 2010-11-17 2016-10-25 中外製薬株式会社 血液凝固第ｖｉｉｉ因子の機能を代替する機能を有する多重特異性抗原結合分子
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
WO2013012648A1 (en) 2011-07-15 2013-01-24 Emory University Gdf15 in diagnostic and therapeutic applications
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN102321173B (zh) 2011-08-12 2013-04-03 中国医学科学院肿瘤研究所 人源化巨噬细胞抑制因子1单克隆抗体及其应用
EP2565262A1 (en) 2011-08-31 2013-03-06 VTU Holding GmbH Protein expression
US9714276B2 (en) 2012-01-26 2017-07-25 Amgen Inc. Growth differentiation factor 15 (GDF-15) polypeptides
CN104853775B (zh) * 2012-09-26 2023-10-20 尤利乌斯·马克西米利安维尔茨堡大学 针对生长和分化因子15(gdf-15)的单克隆抗体
MX370720B (es) 2012-12-21 2019-12-20 Aveo Pharmaceuticals Inc Anticuerpos anti-gdf15.
DK2971156T3 (da) * 2013-03-15 2020-10-19 Myriad Genetics Inc Gener og gensignaturer til diagnosticering og behandling af melanom
JP2015078138A (ja) 2013-10-15 2015-04-23 株式会社ニックス 小動物防除性樹脂組成物
CA2935804A1 (en) * 2014-01-14 2015-07-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
EP2899544B1 (en) * 2014-01-28 2018-12-26 Roche Diagnostics GmbH Biomarkers for risk assessment and treatment monitoring in heart failure patients who receive B-type natriuretic peptide guided therapy
US10010587B2 (en) 2014-02-21 2018-07-03 Nektar Therapeutics IL-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody
PL3197493T3 (pl) 2014-09-25 2021-08-23 Aveo Pharmaceuticals Inc. Sposoby odwracania kacheksji i przedłużania przeżycia obejmujące podanie modulatora gdf15 i środka przeciwnowotworowego
GB201517528D0 (en) 2015-10-02 2015-11-18 Julius Maximillians Universitãt Würzburg GDF-15 as a diagnosis marker for melanoma
CA3000290C (en) 2015-10-02 2023-02-21 Julius-Maximilians-Universitat Wurzburg Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
HRP20221530T1 (hr) 2015-10-02 2023-03-17 Julius-Maximilians-Universität Würzburg Kombinirana terapija uporabom inhibitora ljudskog rasta i faktora diferencijacije 15 (gdf-15) te blokatora imunološke kontrolne točke
TWI803682B (zh) 2018-08-20 2023-06-01 美商輝瑞股份有限公司 抗－ｇｄｆ１５抗體、組成物及使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015144855A1 (en) * 2014-03-26 2015-10-01 Julius-Maximilians-Universität Würzburg Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JAYASHREE P JOSHI ET AL, "Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells", BIOCHEMICAL PHARMACOLOGY, 2011, vol. 82, no. 9, pages 1090 - 1099. *
LAVAUD Pernelle and ANDRE Fabrice, "Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials", BMC Medicine, (2014), Vol.12:132, ISSN 0004112885 *
SUNG JIN HUH ET AL, "Tumorigenesis and Neoplastic Progression Macrophage Inhibitory Cytokine-1 Regulates Melanoma Vascular Development", AM J PATHOL, (2010-06-01), vol. 176, pages 2948 - 2957 *

Also Published As

Publication number Publication date
EP4321866A2 (en) 2024-02-14
KR102621034B1 (ko) 2024-01-03
ES2968226T3 (es) 2024-05-08
US20180292412A1 (en) 2018-10-11
CA3000290A1 (en) 2017-04-06
US12473354B2 (en) 2025-11-18
EP3356827A1 (en) 2018-08-08
CA3000290C (en) 2023-02-21
AU2016333538A1 (en) 2018-04-26
FI3356827T3 (fi) 2024-01-03
WO2017055612A1 (en) 2017-04-06
EP3356827B1 (en) 2023-12-06
DK3356827T3 (da) 2024-01-08
US20220242942A1 (en) 2022-08-04
JP6858181B2 (ja) 2021-04-14
KR20180054867A (ko) 2018-05-24
US11262360B2 (en) 2022-03-01
JP2018535404A (ja) 2018-11-29
EP4321866A3 (en) 2024-03-20

Similar Documents

Publication Publication Date Title
US12473354B2 (en) GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
US20230093412A1 (en) Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
AU2016333540B2 (en) GDF-15 as a diagnostic marker for melanoma
HK1256067B (en) Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
BR112018006218B1 (pt) Uso de inibidores de hgdf-15, kit e combinações
BR122025013944A2 (pt) Inibidores de hgdf-15, seus usos, composição, kit, combinações e método in vitro para determinar se uma substância de interesse é um inibidor de hgdf-15
EA044887B1 (ru) Комбинированное лечение с использованием ингибиторов человеческого фактора роста и дифференцировки 15 (gdf-15) и блокаторов контрольных точек иммунного ответа

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)